Agoraphobia Open Access Scientific Journals
Agoraphobia literally means “fear of the marketplace,” based on agora, the word for the Greek marketplace (Durand & Barlow, 2003). The term “agoraphobia” was first introduced by Westphal in 1871 to describe the fear and avoidance of public places, although this condition was not widely recognized until the late 1970s (Barlow, 2002).Diagnosis of Agoraphobia first appeared in the Diagnostic and Statistical Manual of Mental Disorders in its third edition (DSM-III; American Psychiatric Association [APA],1980). Agoraphobia was then considered a primary diagnosis, which may or may not be accompanied by recurrent panic attacks (Mennin, Heimberg, & Holt, 2000).However, since publication of the DSM-III-R (APA, 1987), a diagnosis of Panic Disorder is considered primary and is diagnosed either with or without Agoraphobia. Under the current DSM-IV (APA, 1994) diagnostic system, individuals exhibiting symptoms of Agoraphobia but never meeting full diagnostic criteria for Panic Disorder are given a diagnosis of Agoraphobia Without
History of Panic Disorder(AWHPD).
The DSM-IV (APA, 1994) describes Agoraphobia as
anxiety about several different places or situations from which escape would be either difficult or embarrassing if some sort of unexpected or unwanted bodily symptoms occurred(Criterion A). As a result, such situations are either avoided, require the presence of a trusted person, or are endured with great distress (Criterion B). This
anxiety and situational avoidance is not better explained by another
anxiety disorder, such as Social Phobia or Specific Phobia (Criterion C). Although panic attacks or “panic-like” bodily sensations are often feared, other feared symptoms include loss of blade-der or bowel control, vomiting, or severe headache. Agoraphobia is not recognized by DSM-IV as a diagnosis on its own. An individual meeting criteria for Agoraphobia is then diagnosed with either Panic Disorder With Agoraphobia(PDA) (if diagnostic criteria for Panic Disorder are also met) or AWHPD. Both diagnoses require that the symptoms cannot be fully explained by a general med-ical condition and do not reflect the direct physiological effects of a substance.
High Impact List of Articles
-
Updated review of nilotinib as frontline treament for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia
Massimo Breccia, Matteo Molica & Giulina Alimena
Drug Evaluation: Clinical Investigation
-
Updated review of nilotinib as frontline treament for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia
Massimo Breccia, Matteo Molica & Giulina Alimena
Drug Evaluation: Clinical Investigation
-
Outcome measures in amyotrophic lateral sclerosis clinical trials
Sabrina Paganoni, Merit Cudkowicz, James D Berry
Clinical Trail Methodology: Clinical Investigation
-
Outcome measures in amyotrophic lateral sclerosis clinical trials
Sabrina Paganoni, Merit Cudkowicz, James D Berry
Clinical Trail Methodology: Clinical Investigation
-
New treatment option for delivering anticancer drugs demonstrated in clinical trial
News and Views: Clinical Investigation
-
New treatment option for delivering anticancer drugs demonstrated in clinical trial
News and Views: Clinical Investigation
-
Peripheral T-cell lymphoma: pharmacotherapy overview
Maher Abdul-Hay, Jasmine Zain
Review: Clinical Trail Outcomes: Clinical Investigation
-
Peripheral T-cell lymphoma: pharmacotherapy overview
Maher Abdul-Hay, Jasmine Zain
Review: Clinical Trail Outcomes: Clinical Investigation
-
Design, findings and implications of the liraglutide Phase III clinical trial program
Bruce W Bode
Review: Clinical Trail Outcomes: Clinical Investigation
-
Design, findings and implications of the liraglutide Phase III clinical trial program
Bruce W Bode
Review: Clinical Trail Outcomes: Clinical Investigation
-
Development of antibiotics for Gram-negatives: where now?
Matteo Bassetti, Francesca Ginocchio, Daniele Roberto, Giacobbe, Malgorzata Mikulska
Therapeutic Prospective: Clinical Investigation
-
Development of antibiotics for Gram-negatives: where now?
Matteo Bassetti, Francesca Ginocchio, Daniele Roberto, Giacobbe, Malgorzata Mikulska
Therapeutic Prospective: Clinical Investigation
Relevant Topics in Clinical